Seek Returns logo

ABBV vs. META: A Head-to-Head Stock Comparison

Updated on

Here’s a clear look at ABBV and META, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

SymbolABBVMETA
Company NameAbbVie Inc.Meta Platforms, Inc.
CountryUnited StatesUnited States
GICS SectorHealth CareCommunication Services
GICS IndustryBiotechnologyInteractive Media & Services
Market Capitalization406.64 billion USD1,797.84 billion USD
ExchangeNYSENasdaqGS
Listing DateJanuary 2, 2013May 18, 2012
Security TypeCommon StockCommon Stock

Historical Performance

This chart compares the performance of ABBV and META by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

ABBV vs. META: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

SymbolABBVMETA
5-Day Price Return-0.58%-2.55%
13-Week Price Return22.68%-0.37%
26-Week Price Return11.60%22.13%
52-Week Price Return17.77%22.80%
Month-to-Date Return-0.58%-2.55%
Year-to-Date Return29.54%22.23%
10-Day Avg. Volume7.35M13.51M
3-Month Avg. Volume5.73M12.02M
3-Month Volatility24.02%31.01%
Beta0.361.29

Profitability

Return on Equity (TTM)

ABBV

95.59%

Biotechnology Industry

Max
97.92%
Q3
11.99%
Median
-19.30%
Q1
-51.29%
Min
-132.03%

In the upper quartile for the Biotechnology industry, ABBV’s Return on Equity of 95.59% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

META

39.33%

Interactive Media & Services Industry

Max
49.37%
Q3
33.08%
Median
10.37%
Q1
5.76%
Min
-24.17%

In the upper quartile for the Interactive Media & Services industry, META’s Return on Equity of 39.33% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

ABBV vs. META: A comparison of their Return on Equity (TTM) against their respective Biotechnology and Interactive Media & Services industry benchmarks.

Net Profit Margin (TTM)

ABBV

6.45%

Biotechnology Industry

Max
73.34%
Q3
18.98%
Median
-12.96%
Q1
-105.72%
Min
-259.82%

ABBV’s Net Profit Margin of 6.45% is aligned with the median group of its peers in the Biotechnology industry. This indicates its ability to convert revenue into profit is typical for the sector.

META

39.99%

Interactive Media & Services Industry

Max
49.74%
Q3
29.54%
Median
20.53%
Q1
7.52%
Min
-14.52%

A Net Profit Margin of 39.99% places META in the upper quartile for the Interactive Media & Services industry, signifying strong profitability and more effective cost management than most of its peers.

ABBV vs. META: A comparison of their Net Profit Margin (TTM) against their respective Biotechnology and Interactive Media & Services industry benchmarks.

Operating Profit Margin (TTM)

ABBV

18.80%

Biotechnology Industry

Max
78.85%
Q3
21.90%
Median
-13.30%
Q1
-109.94%
Min
-278.10%

ABBV’s Operating Profit Margin of 18.80% is around the midpoint for the Biotechnology industry, indicating that its efficiency in managing core business operations is typical for the sector.

META

44.02%

Interactive Media & Services Industry

Max
65.96%
Q3
36.82%
Median
18.53%
Q1
7.69%
Min
-18.13%

An Operating Profit Margin of 44.02% places META in the upper quartile for the Interactive Media & Services industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

ABBV vs. META: A comparison of their Operating Profit Margin (TTM) against their respective Biotechnology and Interactive Media & Services industry benchmarks.

Profitability at a Glance

SymbolABBVMETA
Return on Equity (TTM)95.59%39.33%
Return on Assets (TTM)2.73%25.83%
Net Profit Margin (TTM)6.45%39.99%
Operating Profit Margin (TTM)18.80%44.02%
Gross Profit Margin (TTM)70.93%81.95%

Financial Strength

Current Ratio (MRQ)

ABBV

0.74

Biotechnology Industry

Max
16.97
Q3
8.39
Median
4.11
Q1
2.64
Min
0.74

ABBV’s Current Ratio of 0.74 falls into the lower quartile for the Biotechnology industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

META

1.97

Interactive Media & Services Industry

Max
3.92
Q3
2.72
Median
1.85
Q1
1.20
Min
0.25

META’s Current Ratio of 1.97 aligns with the median group of the Interactive Media & Services industry, indicating that its short-term liquidity is in line with its sector peers.

ABBV vs. META: A comparison of their Current Ratio (MRQ) against their respective Biotechnology and Interactive Media & Services industry benchmarks.

Debt-to-Equity Ratio (MRQ)

ABBV

49.22

Biotechnology Industry

Max
1.92
Q3
0.79
Median
0.12
Q1
0.00
Min
0.00

With a Debt-to-Equity Ratio of 49.22, ABBV operates with exceptionally high leverage compared to the Biotechnology industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.

META

0.15

Interactive Media & Services Industry

Max
0.85
Q3
0.49
Median
0.29
Q1
0.04
Min
0.00

META’s Debt-to-Equity Ratio of 0.15 is typical for the Interactive Media & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

ABBV vs. META: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Biotechnology and Interactive Media & Services industry benchmarks.

Interest Coverage Ratio (TTM)

ABBV

2.70

Biotechnology Industry

Max
72.37
Q3
1.03
Median
-9.59
Q1
-65.05
Min
-163.11

ABBV’s Interest Coverage Ratio of 2.70 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.

META

168.41

Interactive Media & Services Industry

Max
23.65
Q3
16.48
Median
6.73
Q1
-0.87
Min
-3.62

With an Interest Coverage Ratio of 168.41, META demonstrates a superior capacity to service its debt, placing it well above the typical range for the Interactive Media & Services industry. This stems from either robust earnings or a conservative debt load.

ABBV vs. META: A comparison of their Interest Coverage Ratio (TTM) against their respective Biotechnology and Interactive Media & Services industry benchmarks.

Financial Strength at a Glance

SymbolABBVMETA
Current Ratio (MRQ)0.741.97
Quick Ratio (MRQ)0.481.71
Debt-to-Equity Ratio (MRQ)49.220.15
Interest Coverage Ratio (TTM)2.70168.41

Growth

Revenue Growth

ABBV vs. META: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

ABBV vs. META: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

ABBV

2.74%

Biotechnology Industry

Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

ABBV’s Dividend Yield of 2.74% is exceptionally high, placing it well above the typical range for the Biotechnology industry. While this may seem attractive, an unusually high yield can sometimes be a warning sign, reflecting a falling stock price or market concerns about the dividend’s sustainability.

META

0.29%

Interactive Media & Services Industry

Max
3.07%
Q3
1.27%
Median
0.28%
Q1
0.00%
Min
0.00%

META’s Dividend Yield of 0.29% is consistent with its peers in the Interactive Media & Services industry, providing a dividend return that is standard for its sector.

ABBV vs. META: A comparison of their Dividend Yield (TTM) against their respective Biotechnology and Interactive Media & Services industry benchmarks.

Dividend Payout Ratio (TTM)

ABBV

226.84%

Biotechnology Industry

Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

At 226.84%, ABBV’s Dividend Payout Ratio is exceptionally high, exceeding the typical range for the Biotechnology industry. While this provides a significant return to shareholders, it may limit funds for reinvestment and could be difficult to sustain.

META

7.26%

Interactive Media & Services Industry

Max
101.53%
Q3
40.64%
Median
0.00%
Q1
0.00%
Min
0.00%

META’s Dividend Payout Ratio of 7.26% is within the typical range for the Interactive Media & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.

ABBV vs. META: A comparison of their Dividend Payout Ratio (TTM) against their respective Biotechnology and Interactive Media & Services industry benchmarks.

Dividend at a Glance

SymbolABBVMETA
Dividend Yield (TTM)2.74%0.29%
Dividend Payout Ratio (TTM)226.84%7.26%

Valuation

Price-to-Earnings Ratio (TTM)

ABBV

109.81

Biotechnology Industry

Max
40.44
Q3
39.37
Median
22.12
Q1
15.76
Min
3.48

At 109.81, ABBV’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Biotechnology industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.

META

24.96

Interactive Media & Services Industry

Max
50.72
Q3
41.60
Median
25.84
Q1
18.18
Min
1.76

META’s P/E Ratio of 24.96 is within the middle range for the Interactive Media & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.

ABBV vs. META: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Biotechnology and Interactive Media & Services industry benchmarks.

Price-to-Sales Ratio (TTM)

ABBV

7.08

Biotechnology Industry

Max
92.67
Q3
41.36
Median
8.45
Q1
4.46
Min
0.97

ABBV’s P/S Ratio of 7.08 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

META

9.98

Interactive Media & Services Industry

Max
23.76
Q3
11.40
Median
7.69
Q1
2.49
Min
0.00

META’s P/S Ratio of 9.98 aligns with the market consensus for the Interactive Media & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

ABBV vs. META: A comparison of their Price-to-Sales Ratio (TTM) against their respective Biotechnology and Interactive Media & Services industry benchmarks.

Price-to-Book Ratio (MRQ)

ABBV

261.01

Biotechnology Industry

Max
22.72
Q3
10.68
Median
4.55
Q1
2.44
Min
0.59

At 261.01, ABBV’s P/B Ratio is at an extreme premium to the Biotechnology industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.

META

9.51

Interactive Media & Services Industry

Max
16.71
Q3
9.00
Median
3.97
Q1
2.19
Min
0.33

META’s P/B Ratio of 9.51 is in the upper tier for the Interactive Media & Services industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.

ABBV vs. META: A comparison of their Price-to-Book Ratio (MRQ) against their respective Biotechnology and Interactive Media & Services industry benchmarks.

Valuation at a Glance

SymbolABBVMETA
Price-to-Earnings Ratio (TTM)109.8124.96
Price-to-Sales Ratio (TTM)7.089.98
Price-to-Book Ratio (MRQ)261.019.51
Price-to-Free Cash Flow Ratio (TTM)22.6635.60